$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415030595 Filed on May 14, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q2
Revenue	$40.00K	$40.00K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$120.0K	$1.030M	$450.0K
YoY Change	-73.33%	-11.97%	9.76%
% of Gross Profit
Research & Development	$840.0K	$235.3K	$1.090M
YoY Change	-22.94%	-75.66%	122.45%
% of Gross Profit
Depreciation & Amortization	$40.00K	$40.00K	$110.0K
YoY Change	-63.64%	-55.56%	22.22%
% of Gross Profit
Operating Expenses	$960.0K	$235.3K	$1.640M
YoY Change	-41.46%	-75.66%	65.66%
Operating Profit
YoY Change
Interest Expense	$0.00	-$2.080K	$0.00
YoY Change		-88.32%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$10.00K
YoY Change
Pretax Income	-$910.0K	-$1.227M	-$3.670M
YoY Change	-75.2%	-42.93%	90.16%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$910.0K	-$1.227M	-$3.670M
YoY Change	-75.2%	-42.84%	90.16%
Net Earnings / Revenue	-2275.0%	-3067.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.138M	-$1.757M	-$7.058M
COMMON SHARES
Basic Shares Outstanding	16.39M shares	13.87M shares	6.906M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.330M	$470.0K	$6.110M
YoY Change	-45.5%	-92.42%	281.88%
Cash & Equivalents	$3.335M	$470.0K	$6.111M
Short-Term Investments
Other Short-Term Assets	$400.0K	$130.0K	$1.070M
YoY Change	-62.62%	-89.17%	-44.27%
Inventory
Prepaid Expenses			$1.070M
Receivables	$0.00		$43.13K
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$3.730M	$600.0K	$7.224M
YoY Change	-48.37%	-91.89%	105.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$185.9K	$230.0K	$223.5K
YoY Change	-16.79%	7587.17%	4806.15%
Goodwill	$5.781M		$13.90M
YoY Change	-58.42%
Intangibles			$2.179M
YoY Change			-38.91%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$10.00K
YoY Change	400.0%	400.0%	0.0%
Total Long-Term Assets	$15.82M	$16.32M	$26.11M
YoY Change	-39.42%	358.2%	630.11%
TOTAL ASSETS
Total Short-Term Assets	$3.730M	$600.0K	$7.224M
Total Long-Term Assets	$15.82M	$16.32M	$26.11M
Total Assets	$19.55M	$16.92M	$33.33M
YoY Change	-41.36%	54.38%	369.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$232.0K	$660.0K	$901.2K
YoY Change	-74.25%	103.12%	41.4%
Accrued Expenses	$408.7K	$830.0K	$924.0K
YoY Change	-55.77%	13.64%	138.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$778.5K	$1.660M	$1.825M
YoY Change	-57.35%	57.3%	-43.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$122.0K	$140.0K	$99.73K
YoY Change	22.37%	40.38%	0.0%
Total Long-Term Liabilities	$122.0K	$140.0K	$99.73K
YoY Change	22.37%	40.38%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$778.5K	$1.660M	$1.825M
Total Long-Term Liabilities	$122.0K	$140.0K	$99.73K
Total Liabilities	$7.323M	$5.710M	$5.845M
YoY Change	25.28%	394.35%	76.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.2M
YoY Change
Common Stock	$187.5K	$139.8K	$138.5K
YoY Change	35.44%	102.61%	509.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.22M	$11.21M	$27.49M
YoY Change
Total Liabilities & Shareholders Equity	$19.55M	$16.92M	$33.33M
YoY Change	-41.36%	54.38%	369.65%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q2
OPERATING ACTIVITIES
Net Income	-$910.0K	-$1.227M	-$3.670M
YoY Change	-75.2%	-42.84%	90.16%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$110.0K
YoY Change	-63.64%	-55.56%	22.22%
Cash From Operating Activities	-$2.420M	-$1.450M	-$1.220M
YoY Change	98.36%	-7.05%	29.79%
INVESTING ACTIVITIES
Capital Expenditures	$460.0K	-$190.0K	-$220.0K
YoY Change	-309.09%	18.75%	57.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$1.270M
YoY Change	-100.0%
Cash From Investing Activities	$460.0K	-$190.0K	$1.060M
YoY Change	-56.6%	18.75%	-857.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.830M	0.000	70.00K
YoY Change	6800.0%	-100.0%	-93.64%
NET CHANGE
Cash From Operating Activities	-2.420M	-1.450M	-1.220M
Cash From Investing Activities	460.0K	-190.0K	1.060M
Cash From Financing Activities	4.830M	0.000	70.00K
Net Change In Cash	2.870M	-1.640M	-90.00K
YoY Change	-3288.89%	-2442.86%	-550.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.420M	-$1.450M	-$1.220M
Capital Expenditures	$460.0K	-$190.0K	-$220.0K
Free Cash Flow	-$2.880M	-$1.260M	-$1.000M
YoY Change	188.0%	-10.0%	25.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	223475	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	7224398	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2178867	USD
CY2014Q2	svon	Acquired Research And Development AcquiredResearchAndDevelopment	9800000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	13902917	USD
CY2014Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5171	USD
CY2014Q2	us-gaap	Assets Assets	33334828	USD
CY2015Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	105478850	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6111340	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	128167	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1113058	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	901180	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	923990	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	4	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	6	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	138463	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	115631726	USD
CY2014Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	88280265	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3920000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	99728	USD
CY2014Q2	us-gaap	Liabilities Liabilities	5844898	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	139751	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	116545088	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1825170	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	11205993	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	27489930	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16919756	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33334828	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	283393	USD
CY2014Q4	us-gaap	Goodwill Goodwill	13902917	USD
CY2014Q4	svon	Acquired Research And Development AcquiredResearchAndDevelopment	9800000	USD
CY2014Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8121966	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4331080	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6245300	shares
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	408977	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	22685	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	22685	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2842218	shares
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	268720	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	498402	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	735977	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	877573	USD
	svon	Unrecognized Share Based Compensation Expense UnrecognizedShareBasedCompensationExpense	969000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P44M
CY2014Q2	svon	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	345
	svon	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice	0
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	17601	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0099	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	979304	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1192336	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	svon	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	90537	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3397	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2077706	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1179607	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.56
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.73
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.09
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	301.70
CY2014Q2	svon	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	2.65
CY2015Q1	svon	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	0.54
CY2015Q1	svon	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	140.0
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13975140	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13846361	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13975140	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13846361	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3838200	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13889921	shares
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5024265	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1236431	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8470476	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17198584	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	966344	USD
CY2014Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8121966	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	185161	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2290836	USD
	us-gaap	Costs And Expenses CostsAndExpenses	17195209	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-17811	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2080	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-80146	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	703	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2146754	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-1227075	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5550725	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17157006	USD
CY2014Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2877511	USD
CY2015Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	9356	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2919751	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	41578	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5024265	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1236431	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8470476	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17198584	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5806353	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13958261	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-315141	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	45599	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-312384	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-249212	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	333845	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-98176	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	112500	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	877573	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	-14500	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	-19003	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	238904	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	138956	USD
	svon	Writeoff Of Prepaid Research Supplies WriteoffOfPrepaidResearchSupplies	0	USD
	svon	Writeoff Of Prepaid Research Supplies WriteoffOfPrepaidResearchSupplies	669750	USD
	svon	Deferred Rent DeferredRent	0	USD
	svon	Deferred Rent DeferredRent	-99250	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-719349	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3649873	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4924021	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117258	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-409637	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-717339	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10842325	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8655243	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4595733	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5641360	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1602294	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6198027	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	731	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2	USD
	us-gaap	Stock Issued1 StockIssued1	89885	USD
	us-gaap	Stock Issued1 StockIssued1	41578	USD
	svon	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	29000	USD
	svon	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	19003	USD
	us-gaap	Interest Paid InterestPaid	85629	USD
	us-gaap	Interest Paid InterestPaid	2209	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1 - Basis of Presentation:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The financial statements included herein have been prepared by Sevion Therapeutics, Inc. (the “Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 29, 2014, the Company changed its name from Senesco Technologies, Inc. to Sevion Therapeutics, Inc.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of March 31, 2015 and the results of its operations for the three and nine months ended March 31, 2015 and cash flows for the nine months ended March 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior year amounts have been reclassified from general and administrative expenses to research and development expenses for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows from operations in the Consolidated Condensed Statement of Cash Flows, and had no effect on the previously reported Consolidated Condensed Statement of Operations for any period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Interim results are not necessarily indicative of results for the full fiscal year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Sevion Therapeutics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001035354
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	SVON
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16387522	shares
CY2015Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	173234	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2187082	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	svon	Probability To Achieve Employee Target Goals ProbabilityToAchieveEmployeeTargetGoals	0.69	pure

Files In Submission

Name	View Source	Status
0001144204-15-030595-index-headers.html	Edgar Link	pending
0001144204-15-030595-index.html	Edgar Link	pending
0001144204-15-030595.txt	Edgar Link	pending
0001144204-15-030595-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
svon-20150331.xml	Edgar Link	completed
svon-20150331.xsd	Edgar Link	pending
svon-20150331_cal.xml	Edgar Link	unprocessable
svon-20150331_def.xml	Edgar Link	unprocessable
svon-20150331_lab.xml	Edgar Link	unprocessable
svon-20150331_pre.xml	Edgar Link	unprocessable
v409314_10q.htm	Edgar Link	pending
v409314_ex10-1.htm	Edgar Link	pending
v409314_ex31-1.htm	Edgar Link	pending
v409314_ex31-2.htm	Edgar Link	pending
v409314_ex32-1.htm	Edgar Link	pending
v409314_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2015 Q2 Form 10-Q Financial Statement

#000114420415030595 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2015 Q2 Form 10-Q Financial Statement

#000114420415030595 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox